A citation-based method for searching scientific literature

Mark Lebwohl, Andrew Blauvelt, Carle Paul, Howard Sofen, Jolanta Węgłowska, Vincent Piguet, Daniel Burge, Robert Rolleri, Janice Drew, Luke Peterson, Matthias Augustin. J Am Acad Dermatol 2018
Times Cited: 70



Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin M Valdes, Elizabeth H Z Thompson, Hervé Bachelez. Lancet 2018
Times Cited: 254




List of shared articles



Times cited

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
Craig L Leonardi, Kyoungah See, Russel Burge, Zhuoer Sun, Ying Zhang, Lotus Mallbris, Alyssa Garrelts, Richard B Warren. Adv Ther 2022
0

Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.
Kyle Fahrbach, Grammati Sarri, David M Phillippo, Binod Neupane, Samantha E Martel, Sandeep Kiri, Kristian Reich. Dermatol Ther (Heidelb) 2021
3

A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains.
Tiago Torres, Anabela Barcelos, Paulo Filipe, João Eurico Fonseca. Front Med (Lausanne) 2021
4

Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.
Abby S Van Voorhees, Marc A Mason, Leslie R Harrold, Ning Guo, Adriana Guana, Haijun Tian, Vivian Herrera, Bruce E Strober. J Dermatolog Treat 2021
3

Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
U Mrowietz, R B Warren, C L Leonardi, D Saure, H Petto, S Hartz, M Dossenbach, K Reich. J Eur Acad Dermatol Venereol 2021
4

State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.
Paolo Gisondi, Davide Geat, Miriam Pizzolato, Giampiero Girolomoni. Curr Opin Pharmacol 2019
18

New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.
Di Yan, Andrew Blauvelt, Amit K Dey, Rachel S Golpanian, Samuel T Hwang, Nehal N Mehta, Bridget Myers, Zhen-Rui Shi, Gil Yosipovitch, Stacie Bell,[...]. J Invest Dermatol 2021
4

What's New in Psoriasis.
Stephanie von Csiky-Sessoms, Mark Lebwohl. Dermatol Clin 2019
13

Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.
Neil H Shear, Keith A Betts, Ahmed M Soliman, Avani Joshi, Yan Wang, Jing Zhao, Paolo Gisondi, Ranjeeta Sinvhal, April W Armstrong. J Am Acad Dermatol 2021
4

Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren. PLoS One 2019
67


Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.
Najeeda Yasmeen, Laura M Sawyer, Kinga Malottki, Lars-Åke Levin, Eydna Didriksen Apol, Gregor B Jemec. J Dermatolog Treat 2022
16


Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.
Nicholas D Brownstone, Quinn G Thibodeaux, Vidhatha D Reddy, Bridget A Myers, Stephanie Y Chan, Tina Bhutani, Wilson Liao. Dermatol Ther (Heidelb) 2020
21

Safety concerns with current treatments for psoriasis in the elderly.
Roberta Di Caprio, Giuseppina Caiazzo, Sara Cacciapuoti, Gabriella Fabbrocini, Emanuele Scala, Anna Balato. Expert Opin Drug Saf 2020
8

Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.
Shanshan Xu, Xing Gao, Jixiang Deng, Jiajia Yang, Faming Pan. J Dtsch Dermatol Ges 2021
3

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Richard B Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg. Dermatol Ther (Heidelb) 2020
17


Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
April W Armstrong, Luis Puig, Avani Joshi, Martha Skup, David Williams, Junlong Li, Keith A Betts, Matthias Augustin. JAMA Dermatol 2020
65

Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
D Thaçi, K Eyerich, A Pinter, M Sebastian, K Unnebrink, S Rubant, D A Williams, P Weisenseel. Br J Dermatol 2022
4

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach. Cochrane Database Syst Rev 2022
0

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach. Cochrane Database Syst Rev 2021
14

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, Alexander Egeberg, Jashin J Wu. Am J Clin Dermatol 2021
11

Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry.
Abby S Van Voorhees, Marc A Mason, Leslie R Harrold, Ning Guo, Adriana Guana, Haijun Tian, Vivian Herrera, Bruce E Strober. J Dermatolog Treat 2021
0

Biologics for chronic inflammatory skin diseases: an update for the clinician.
Yiqiu Yao, Astrid-Helene Ravn Jørgensen, Simon Francis Thomsen. J Dermatolog Treat 2020
8

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab.
Feras M Ghazawi, Farhan Mahmood, Leon Kircik, Yves Poulin, Marc Bourcier, Ronald Vender, Marni C Wiseman, Charles Lynde, Ivan V Litvinov. Front Med (Lausanne) 2021
4

A Brief History of Psoriasis Management in Canada.
Khalad Maliyar, Patrick Fleming, Boluwaji Ogunyemi, Charles Lynde. J Cutan Med Surg 2020
1

How current biologic therapies affect the risk of major adverse cardiovascular events in patients with plaque psoriasis? A systematic review and meta-analysis of randomized controlled trials.
Sonia Nartowicz, Ewelina Jakielska, Monika Priadka, Zygmunt Adamski, Piotr Ratajczak, Krzysztof Kus. Postepy Dermatol Alergol 2020
1

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Sivem Afach, Liz Doney, Corinna Dressler, Camille Hua, Canelle Mazaud, Céline Phan, Carolyn Hughes, Dru Riddle,[...]. Cochrane Database Syst Rev 2020
69

Risankizumab in moderate-to-severe plaque psoriasis.
Linda Serrano, Victoria Maloney, Kenneth B Gordon. Immunotherapy 2019
4

The Role of Helper T Cells in Psoriasis.
Peng Hu, Mengyao Wang, Hu Gao, Ai Zheng, Jinhui Li, Dezhi Mu, Jiyu Tong. Front Immunol 2021
2

Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
Andrew Blauvelt, Russel Burge, William Malatestinic, Alan Brnabic, Jiaying Guo, Manju Janardhanan, Baojin Zhu. J Manag Care Spec Pharm 2021
2

Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
April W Armstrong, Ahmed M Soliman, Keith A Betts, Yan Wang, Yawen Gao, Luis Puig, Matthias Augustin. Dermatol Ther (Heidelb) 2021
11